Figure 3. Association between peri-HCT MRD dynamics and outcome for AML patients following myeloablative HCT, stratified by positive/negative MRD status.

Kaplan-Meier estimates of (A) overall survival and (B) relapse-free survival as well as cumulative incidences of (C) relapse, and (D) non-relapse mortality following myeloablative allogeneic HCT for adults with AML, shown individually for patients with MRD^neg/MRD^neg (n=214), MRD^neg/MRD^pos (n=2), MRD^pos/MRD^neg (n=49) and MRD^pos/MRD^pos (n=14) disease status in the pre/post-HCT bone marrow assessment.